The estimated Net Worth of Manja Boerman is at least $1.31 Milion dollars as of 1 May 2023. Manja Boerman owns over 1,446 units of Catalent stock worth over $859,507 and over the last 2 years he sold CTLT stock worth over $452,043. In addition, he makes $0 as President - Cell & Gene Therapy at Catalent.
Manja has made over 3 trades of the Catalent stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,446 units of CTLT stock worth $72,098 on 1 May 2023.
The largest trade he's ever made was selling 3,296 units of Catalent stock on 24 August 2022 worth over $339,620. On average, Manja trades about 1,841 units every 83 days since 2022. As of 1 May 2023 he still owns at least 14,414 units of Catalent stock.
You can see the complete history of Manja Boerman stock trades at the bottom of the page.
Dr. Manja Boerman Ph.D. has been appointed as President - Cell & Gene Therapy of the Company effective 6/1/2020. Dr. Boerman joined Catalent in December 2019 with more than 20 years' experience in biotech and pharmaceutical services, and significant experience as a senior executive in start-up environments and global late-stage clinical development for cell therapy products. She most recently served as president of Aesica Pharmaceuticals, a UK-based CDMO, and before that as CEO for a Netherlands-based biotech and as Executive Director for Charles Rivers Laboratories where she helped open a new biologics facility in Boston. In addition, she served as president of Patheon Biologics where she significantly grew the customer base and growth path for biologics through organic activities and acquisitions. Manja holds a doctorate in Biochemistry from the State University of New York - Buffalo.
Manja's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius oraz Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: